Race-based medicine, such as Bidil, the F.D.A. approved heart drug that is designed for African Americans, is an important example of why racial categories do not suffice as a determination of human biological diversity. As race-based drugs are being developed, the question as to whether race alone predisposes a person to a disease is still in doubt.
Some geneticists argue that the focus should be on specific genes as the targets of the disease in question. In addition, studies have shown that there is much more variation within a population of a given continent than between continental populations. This large-scale variation within populations makes using race to group people medically controversial and potentially problematic.
The fact is that experts, such as cardiologists in Florida, are committed to providing the best in healthcare and cardiovascular treatment. Race-based drugs present some very crucial matters to how to best care for patients that may be predisposed to heart disease. Although racial groups can serve to narrow down the selection presuming that their genetic background share similarities, it is not entire accurate and it may marginalize people that may have a similar genetic background who are also in need of medical treatment.
To learn more excellence in cardiovascular care visit this Florida cardiologist practice website.